Generation of induced pluripotent stem (iPS) cells derived from a murine model of Pompe disease and differentiation of Pompe-iPS cells into skeletal muscle cells.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2011-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ymgme.2011.05.020PMID 21703893
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized study of alglucosidase alfa in late-onset Pompe's disease.

  2010cited by this paper
• Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.

  2010cited by this paper
• Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells

  2010cited by this paper
• Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders

  2010cited by this paper
• Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy.

  2010cited by this paper
• Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction

  2010cited by this paper
• Progress in enzyme replacement therapy in glycogen storage disease type II

  2009cited by this paper
• Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease

  2009cited by this paper
• Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease

  2009cited by this paper
• Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial

  2009cited by this paper
• Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy.

  2008cited by this paper
• Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

  2008cited by this paper
• Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts

  2008cited by this paper
• Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease

  2007cited by this paper
• Induction of pluripotent stem cells from fibroblast cultures

  2007cited by this paper
• Deconstructing Pompe Disease by Analyzing Single Muscle Fibers: “To See a World in a Grain of Sand…”

  2007cited by this paper
• Broad spectrum of Pompe disease in patients with the same c.-32-13T→G haplotype

  2007cited by this paper
• Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

  2007cited by this paper
• Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease.

  2006cited by this paper
• Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

  2006cited by this paper
• Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease

  2006cited by this paper
• Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.

  2005cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Plat-E: an efficient and stable system for transient packaging of retroviruses

  2000cited by this paper
• Prevalence of lysosomal storage disorders.

  1999cited by this paper
• The liver in generalized glycogen storage disease. Light microscopic observations.

  1966cited by this paper
• The FASEB Journal • Research Communication Generation of transplantable, functional satellite-like

  year unknowncited by this paper

• Mitochondrial dysfunction is associated with hypertrophic cardiomyopathy in Pompe disease‐specific induced pluripotent stem cell‐derived cardiomyocytes

  2023cites this paper
• Induced pluripotent stem cell for modeling Pompe disease

  2022influential citation
• Isogenic GAA-KO Murine Muscle Cell Lines Mimicking Severe Pompe Mutations as Preclinical Models for the Screening of Potential Gene Therapy Strategies

  2022cites this paper
• Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Niemann-Pick Type C1

  2021cites this paper
• Role of induced pluripotent stem cells in lysosomal storage diseases.

  2020cites this paper
• Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

  2019cites this paper
• Generation of an alveolar epithelial type II cell line from induced pluripotent stem cells.

  2018cites this paper
• Induced pluripotent stem cell models of lysosomal storage disorders

  2017cites this paper
• A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells

  2017cites this paper
• Making muscle: skeletal myogenesis in vivo and in vitro

  2017cites this paper
• Engineering Niches for Embryonic and Induced Pluripotent Stem Cells

  2017cites this paper
• Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro

  2016cites this paper
• Natural and Synthetic Materials for Self‐Renewal, Long‐Term Maintenance, and Differentiation of Induced Pluripotent Stem Cells

  2015cites this paper
• The Hope for iPSC in Lung Stem Cell Therapy and Disease Modeling

  2015cites this paper
• Models and therapeutic approaches for Niemann-Pick (A/B and C) and other lysosomal storage disorders

  2015cites this paper
• Pompe disease: literature review and case series.

  2014cites this paper
• The secretome of induced pluripotent stem cells reduces lung fibrosis in part by hepatocyte growth factor

  2014cites this paper
• Ultrastructural Characteristics of Three Undifferentiated Mouse Embryonic Stem Cell Lines and Their Differentiated Three-Dimensional Derivatives: A Comparative Study

  2014cites this paper
• The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-α-glucosidase in Pompe's iPSCs.

  2014cites this paper
• Literature Review and Case Series

  2014cites this paper
• Morphological features of iPS cells generated from Fabry disease skin fibroblasts using Sendai virus vector (SeVdp).

  2013cites this paper
• Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease

  2013cites this paper
• iPS Cell Modeling of Cardiometabolic Diseases

  2013cites this paper
• WITHDRAWN: Clearance of lysosomal glycogen accumulation by Transcription factor EB (TFEB) in muscle cells from lysosomal alpha-glucosidase deficient mice.

  2013cites this paper
• Clearance of lysosomal glycogen accumulation by Transcription factor EB (TFEB) in muscle cells from lysosomal alpha-glucosidase deficient mice

  2013cites this paper
• Craniofacial Reconstruction With Induced Pluripotent Stem Cells

  2012cites this paper
• Amniotic fluid stem cells: a promising therapeutic resource for cell-based regenerative therapy.

  2012cites this paper
• Exploring hurler syndrome through the study of disease-specific multipotent and pluripotent stem cells

  2012cites this paper
• Induced pluripotent stem cells in research and therapy.

  2012cites this paper
• Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.

  2012cites this paper
• Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases

  2012cites this paper
• High Efficiency of Reprogramming CD34+ Cells Derived from Human Amniotic Fluid into Induced Pluripotent Stem Cells with Oct4

  2012cites this paper
• The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease

  2012cites this paper